Watch INBP. Know when insiders buy.
One email the day a filing lands. Free.
INBP
INTEGRATED BIOPHARMA INC
0.17
+0.00 +0.00%
USD · close Sep 17
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $5.3MP/E —DIV YIELD —FCF YIELD 53.77%REV TTM —NET INCOME −$1.7M −231.9%NET CASH $5.8M52W 0.15 – 0.38SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q3 2026 · Mar 31 | — | — | — | −$1.1M | −$837K | −237.0% | -0.03 | $517K | $0 | $517K | May 8 |
| Q2 2026 · Dec 31 | — | — | — | −$914K | −$762K | −756.9% | -0.03 | $617K | $24K | $593K | May 8 |
| Q1 2026 · Sep 30 | — | — | — | $163K | $123K | −52.5% | 0.00 | $1.3M | $173K | $1.1M | May 8 |
| Q4 2025 · Jun 30derived | — | — | — | $589K | −$178K | −166.4% | 0.00 | $591K | −$10K | $601K | Sep 23 |
| Q3 2025 · Mar 31 | — | — | — | $739K | $611K | +114.4% | 0.02 | $616K | $116K | $500K | May 8 |
| Q2 2025 · Dec 31 | — | — | — | $202K | $116K | — | 0.01 | $201K | $29K | $172K | May 8 |
| Q1 2025 · Sep 30 | — | — | — | $490K | $259K | — | 0.01 | $657K | $56K | $601K | May 8 |
| Q4 2024 · Jun 30derived | — | — | — | $402K | $268K | +570.0% | 0.01 | −$186K | $146K | −$332K | Sep 23 |
| Q3 2024 · Mar 31 | — | — | — | $355K | $285K | — | 0.01 | $1.6M | $345K | $1.3M | May 14 |
| Q2 2024 · Dec 31 | — | — | — | −$452K | −$382K | — | -0.01 | −$1.8M | $24K | −$1.9M | May 14 |
| Q1 2024 · Sep 30 | — | — | — | −$54K | −$59K | — | 0.00 | $1.3M | $38K | $1.3M | May 14 |
| Q4 2023 · Jun 30derived | — | — | — | $79K | $40K | — | 0.00 | −$1.2M | $18K | −$1.2M | Sep 20 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Jun 30 | — | — | $2M | $808K | — | 0.03 | $2.1M | $191K | $1.9M | — | — |
| FY2024 · to Jun 30 | — | — | $251K | $112K | — | 0.00 | $943K | $553K | $390K | — | — |
| FY2023 · to Jun 30 | — | — | $120K | −$34K | — | 0.00 | $1.2M | $116K | $1.1M | — | — |
| FY2022 · to Jun 30 | — | — | $2.7M | $3.8M | — | 0.12 | $4.1M | $486K | $3.6M | — | — |
| FY2021 · to Jun 30 | — | — | $5.8M | $8M | — | 0.25 | $3M | $295K | $2.8M | — | — |
| FY2020 · to Jun 30 | — | — | $3.3M | $4.1M | — | 0.13 | $1.3M | $214K | $1.1M | — | — |
Every number comes from INTEGRATED BIOPHARMA INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.